Stock listing
NASDAQ:NRIX Nurix Therapeutics, Inc. Stock
Home listing (NASDAQ) of Nurix Therapeutics, Inc.
Follow Nurix Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:NRIX
$12.85 USD -1.25 (-8.9%)
Close on Nov 20, 2026
- Day range
- $12.83 – $13.67 USDNov 20, 2026
- Volume
- 2.43M sharesNov 20, 2026
- Market cap
- $1.40B USDAt the close on Nov 20, 2026 · price × 109.2M shares outstanding
- 52-week range
- $12.83 – $28.23 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $52.17M USDMedian day 1.91M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NRIX · Home | $12.85 USD | -1.25 (-8.9%) | 2,433,363 | $13.40 | $13.67 | $12.83 | $14.10 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NRIX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $12.85 | -1.25 | -8.9% | $13.40 | $13.67 | $12.83 | 2,433,363 | |
| $14.10 | -0.14 | -1.0% | $14.15 | $14.44 | $13.65 | 2,789,967 | |
| $14.24 | -0.49 | -3.3% | $14.80 | $14.86 | $14.11 | 2,224,931 | |
| $14.73 | -0.75 | -4.8% | $15.34 | $15.60 | $14.68 | 2,156,608 | |
| $15.48 | -0.12 | -0.8% | $15.50 | $15.76 | $15.19 | 1,384,643 | |
| $15.60 | -0.73 | -4.5% | $16.38 | $16.55 | $15.55 | 1,338,383 | |
| $16.33 | +0.45 | +2.8% | $16.00 | $16.70 | $15.92 | 2,513,606 | |
| $15.88 | -0.26 | -1.6% | $16.00 | $16.76 | $15.75 | 3,049,883 | |
| $16.14 | +0.84 | +5.5% | $15.32 | $16.62 | $15.27 | 5,974,105 | |
| $15.30 | +0.46 | +3.1% | $15.10 | $15.52 | $14.79 | 2,974,181 | |
| $14.84 | -1.11 | -7.0% | $16.01 | $16.59 | $14.80 | 7,091,384 | |
| $15.95 | -9.87 | -38.2% | $17.16 | $17.28 | $14.78 | 19,559,090 | |
| $25.82 | +0.12 | +0.5% | $25.72 | $26.55 | $25.63 | 4,386,939 | |
| $25.70 | -1.10 | -4.1% | $26.75 | $26.96 | $25.53 | 2,348,536 | |
| $26.80 | -0.32 | -1.2% | $26.90 | $26.92 | $25.97 | 2,311,400 | |
| $27.12 | -0.14 | -0.5% | $27.46 | $27.99 | $26.69 | 2,375,000 | |
| $27.26 | +0.56 | +2.1% | $26.26 | $27.28 | $25.45 | 1,957,400 | |
| $26.70 | +1.15 | +4.5% | $25.52 | $27.05 | $25.13 | 2,563,000 | |
| $25.55 | +0.21 | +0.8% | $25.35 | $25.82 | $25.03 | 2,336,900 | |
| $25.34 | -0.17 | -0.7% | $25.22 | $25.49 | $24.78 | 1,910,400 | |
| $25.51 | -0.51 | -2.0% | $25.86 | $26.23 | $25.18 | 1,933,900 | |
| $26.02 | -0.08 | -0.3% | $26.00 | $26.31 | $25.80 | 2,928,300 | |
| $26.10 | +1.17 | +4.7% | $24.92 | $26.34 | $24.71 | 3,979,800 | |
| $24.93 | +0.51 | +2.1% | $24.57 | $25.29 | $24.38 | 3,064,100 | |
| $24.42 | -0.53 | -2.1% | $24.89 | $25.36 | $24.27 | 4,318,300 | |
| $24.95 | +1.28 | +5.4% | $23.67 | $25.14 | $23.61 | 3,753,400 | |
| $23.67 | +1.54 | +7.0% | $22.01 | $24.01 | $21.40 | 3,820,700 | |
| $22.13 | -0.03 | -0.1% | $22.16 | $23.24 | $21.75 | 4,680,800 | |
| $22.16 | -0.19 | -0.9% | $22.27 | $22.58 | $22.03 | 2,850,900 | |
| $22.35 | +0.14 | +0.6% | $22.04 | $23.23 | $21.23 | 1,525,100 | |
| $22.21 | -0.52 | -2.3% | $22.49 | $22.60 | $21.55 | 2,344,900 | |
| $22.73 | +0.13 | +0.6% | $22.43 | $23.10 | $22.18 | 1,631,800 | |
| $22.60 | -0.28 | -1.2% | $23.06 | $23.06 | $22.10 | 1,154,200 | |
| $22.88 | -0.11 | -0.5% | $22.81 | $23.31 | $22.43 | 1,006,500 | |
| $22.99 | -0.35 | -1.5% | $23.72 | $23.75 | $22.85 | 815,500 | |
| $23.34 | -0.37 | -1.6% | $23.60 | $23.99 | $23.21 | 1,334,900 | |
| $23.71 | +0.035 | +0.1% | $23.85 | $23.94 | $23.34 | 2,010,700 | |
| $23.68 | +0.005 | 0.0% | $23.57 | $23.91 | $23.25 | 2,275,400 | |
| $23.67 | +0.66 | +2.9% | $22.86 | $23.69 | $22.41 | 2,007,900 | |
| $23.01 | -0.64 | -2.7% | $23.78 | $23.81 | $22.98 | 1,540,100 | |
| $23.65 | -0.23 | -1.0% | $23.76 | $23.93 | $23.02 | 2,023,100 | |
| $23.88 | -1.79 | -7.0% | $25.49 | $25.56 | $23.85 | 1,364,000 | |
| $25.67 | +0.26 | +1.0% | $25.32 | $25.96 | $25.23 | 1,509,600 | |
| $25.41 | -0.03 | -0.1% | $25.73 | $25.93 | $25.06 | 1,516,700 | |
| $25.44 | -0.06 | -0.2% | $25.32 | $25.80 | $25.01 | 2,839,500 | |
| $25.50 | +0.35 | +1.4% | $25.79 | $26.35 | $25.37 | 1,511,900 | |
| $25.15 | +0.32 | +1.3% | $24.87 | $25.29 | $24.68 | 1,236,400 | |
| $24.83 | -0.69 | -2.7% | $25.47 | $25.50 | $24.27 | 1,251,000 | |
| $25.52 | +0.42 | +1.7% | $25.01 | $26.14 | $24.95 | 1,330,800 | |
| $25.10 | -0.71 | -2.8% | $26.31 | $26.65 | $25.00 | 1,321,700 | |
| $25.81 | -0.45 | -1.7% | $25.89 | $25.99 | $25.50 | 1,029,500 | |
| $26.26 | +0.13 | +0.5% | $26.46 | $26.70 | $25.91 | 1,027,400 | |
| $26.13 | -0.01 | 0.0% | $25.42 | $26.42 | $25.36 | 1,287,900 | |
| $26.14 | +0.82 | +3.2% | $25.19 | $26.22 | $24.97 | 1,232,100 | |
| $25.32 | -0.50 | -1.9% | $25.82 | $26.16 | $24.95 | 1,381,500 | |
| $25.82 | -0.22 | -0.8% | $26.35 | $26.92 | $25.39 | 1,736,100 | |
| $26.04 | +0.26 | +1.0% | $25.47 | $26.11 | $25.47 | 1,597,400 | |
| $25.78 | -0.43 | -1.6% | $26.00 | $26.23 | $25.17 | 1,244,200 | |
| $26.21 | -0.665 | -2.5% | $26.52 | $26.87 | $26.13 | 929,200 | |
| $26.88 | +0.165 | +0.6% | $26.80 | $27.50 | $26.24 | 1,256,800 | |
| $26.71 | -0.24 | -0.9% | $26.77 | $27.23 | $26.44 | 551,900 | |
| $26.95 | +0.68 | +2.6% | $26.72 | $27.38 | $26.38 | 1,176,300 | |
| $26.27 | -0.45 | -1.7% | $26.37 | $26.69 | $25.86 | 874,200 | |
| $26.72 | -0.33 | -1.2% | $27.41 | $27.50 | $26.70 | 1,485,900 | |
| $27.05 | -0.74 | -2.7% | $27.33 | $27.57 | $26.68 | 1,086,900 |
- Ticker
- NASDAQ:NRIX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Latest deck · Oct 29, 2026
9th Annual TPD & Induced Proximity Summit (October 2026)
Conference · 35 slides
Latest news
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Nov 11, 2026
Closed $16.33 (+2.8%) on Nov 11, 2026
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nov 10, 2026
Closed $15.88 (-1.6%) on Nov 10, 2026
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
Nov 5, 2026
Closed $14.84 (-7.0%) on Nov 5, 2026
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
Nov 3, 2026
Closed $15.95 (-38.2%) on Nov 4, 2026
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Oct 12, 2026
Closed $22.13 (-0.1%) on Oct 13, 2026
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
Oct 6, 2026
Closed $22.60 (-1.2%) on Oct 6, 2026
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Oct 5, 2026
Closed $22.88 (-0.5%) on Oct 5, 2026
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
Sep 29, 2026
Closed $23.68 (0.0%) on Sep 29, 2026
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
Sep 1, 2026
Closed $26.04 (+1.0%) on Sep 1, 2026
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
Aug 20, 2026
Closed $27.05 (-2.7%) on Aug 20, 2026
Nurix Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 29 in the last 12 months · 182 in all · newest Nov 11, 2026 · oldest 2020
- Decks
- 35 decks · latest Oct 29, 2026
Where Nurix Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NRIX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:NRIX | BOATS | United States | USD |
Valuation
EV/sales 1.0× against a median of 19.0×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Aug 31, 2026 · price Nov 20, 2026
- Enterprise value
- $683.6M USD
- P/E
- 4.8×
- EV/sales
- 1.0×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.4×
- Gross margin
- Not reported
- Operating margin
- 41.3%
- Net margin
- 42.0%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.15
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. · NASDAQ:NRIX | US$1.40B | US$683.6M | 4.8× | 1.0× | n/a | 1.4× | 42.0% | 0.0× | 1.15 |
| Vir Biotechnology, Inc. · NASDAQ:VIR | US$1.44B | US$1.07B | n/a | 3.5× | n/a | 1.6× | −61.0% | 0.1× | 1.82 |
| Voronoi, Inc. · KRX:310210 | US$1.44B | US$1.39B | n/a | n/a | n/a | 27.9× | n/a | 0.5× | n/a |
| Kailera Therapeutics, Inc. · NASDAQ:KLRA | US$1.43B | US$539.5M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.28 |
| Sarepta Therapeutics, Inc. · NASDAQ:SRPT | US$1.43B | US$1.41B | n/a | 0.7× | n/a | 0.9× | −5.9% | 0.6× | 1.70 |
| LigaChem Biosciences Inc. · KRX:141080 | US$1.42B | US$1.14B | n/a | 15.5× | n/a | 4.8× | −180.9% | 0.0× | n/a |
| ADARx Pharmaceuticals, Inc. · NASDAQ:ADRX | US$1.42B | US$521.8M | n/a | 77.6× | n/a | 2.5× | n/a | 0.0× | n/a |
| Intellia Therapeutics, Inc. · NASDAQ:NTLA | US$1.40B | US$1.00B | n/a | 19.0× | n/a | 2.3× | −805.7% | 0.1× | 2.01 |
| Tyra Biosciences, Inc. · NASDAQ:TYRA | US$1.39B | US$694.9M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 0.40 |
| Wuhan Healthgen Biotechnology Corp Class A · SSE:688765 | US$1.38B | US$1.38B | n/a | 164× | n/a | 3.3× | −252.8% | 0.1× | n/a |
| Rapport Therapeutics, Inc. · NASDAQ:RAPP | US$1.37B | US$987.3M | n/a | 49.4× | n/a | 3.5× | −752.4% | 0.0× | 1.16 |
| Median of the others | US$1.42B | US$1.04B | 19.0× | 2.4× | −216.9% | 0.1× | 1.49 |
Forecasts
8 strong buy · 5 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 33.50 USD · Analysts' mean
- EPS, year to Nov 2026
- 3.02 · 3 analysts
- Revenue, year to Nov 2026
- 744.8M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Arthur T. Sands | President, Chief Executive Officer, and Board Director |
| Arati V. Rao | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Julia P. Gregory | Chair |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 12, 2026 | −1.0% |
| Q2 2026 | Jul 9, 2026 · After close | −6.6% |
| Q1 2026 | Apr 14, 2026 | +6.7% |
| Q4 2025 | Jan 28, 2026 · After close | −1.6% |
| Q3 2025 | Oct 9, 2025 · After close | −10.1% |
| Q2 2025 | Jul 9, 2025 · After close | −3.9% |
| Q1 2025 | Apr 8, 2025 · After close | +3.7% |
| Q4 2024 | Feb 13, 2025 · Before open | +1.5% |
| Q3 2024 | Oct 11, 2024 · After close | +6.5% |
| Q2 2024 | Jul 11, 2024 · After close | +8.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 10, 2024 · Before open | −10.2% |
| Q4 2023 | Feb 15, 2024 · After close | +0.2% |
| Q3 2023 | Oct 12, 2023 · After close | +2.3% |
| Q2 2023 | Jul 13, 2023 · After close | −3.2% |
| Q1 2023 | Apr 13, 2023 · After close | +20.6% |
| Q4 2022 | Feb 9, 2023 · After close | +3.7% |
| Q3 2022 | Oct 6, 2022 · After close | −7.2% |
| Q2 2022 | Jul 7, 2022 · After close | +14.5% |
| Q1 2022 | Apr 8, 2022 · After close | −16.5% |
| Q4 2021 | Jan 27, 2022 · After close | +2.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 9th Annual TPD & Induced Proximity Summit (October 2026) | Conference | 35 slides | Oct 29, 2026 |
| EHA 2026 Annual Meeting | Conference | 15 slides | Jun 14, 2026 |
| Merger or Acquisition (June 2026) | Merger or acquisition | 19 slides | Jun 8, 2026 |
| Technical Presentation (April 2026) | Technical | 21 slides | April 2026 |
| J.P. Morgan Healthcare Conference 2026 | Conference | 27 slides | Jan 12, 2026 |
| ASH 2025 (American Society of Hematology annual meeting) | Conference | 47 slides | Dec 9, 2025 |
| Investor Presentation (October 2025) | Investor deck | 53 slides | Oct 22, 2025 |
| Investor Presentation (September 2025) | Investor deck | 12 slides | Sep 3, 2025 |
| EHA 2025 Investor Event | Conference | 35 slides | Jun 12, 2025 |
| Investor Presentation (January 2025) | Investor deck | 31 slides | Jan 13, 2025 |
All 35 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$250M raised · US$10.21 a share · J.P. Morgan Securities LLC +4 Dealers: J.P. Morgan Securities LLC (co-lead), Jefferies LLC (co-lead), Stifel, Nicolaus & Company, Incorporated (co-lead), Oppenheimer & Co. Inc., Robert W. Baird & Co. Incorporated Buyers: General Atlantic; Redmile Group; Braidwell LP; Deep Track Capital; Perceptive Advisors; Trails Edge Capital Partners; Vestal Point Capital Use of proceeds: Clinical development of drug candidates incl. bexobrutideg in CLL and autoimmune indications, R&D to expand pipeline, working capital and general purposes | Oct 27, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$19.00 a share on Jul 23, 2020.
- Price
- US$19.00 a share
- Shares offered
- 11,000,000 shares of common stock
- Offering size
- US$209 million
- Underwriters' option
- Up to 1,650,000 more shares
- Underwriters
- J.P. Morgan, Piper Sandler, Stifel, Needham & Company · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 5, 2020 |
| Filed publicly | Jul 2, 2020 |
| Amended twice | Newest Jul 23, 2020 |
| Shares registered with an exchange | Jul 20, 2020 |
| Declared effective by the SEC | Jul 23, 2020 |
| Final prospectus, with the price | Jul 24, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 24, 2020 |
| EFFECT · Notice that a registration is effective | Jul 23, 2020 |
| CERT · Exchange's certificate of listing | Jul 23, 2020 |
| S-1/A · Registration statement, amended | Jul 23, 2020 |
| CORRESP · Letter to the SEC | Jul 21, 2020 |
| CORRESP · Letter to the SEC | Jul 21, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 20, 2020 |
| S-1/A · Registration statement, amended | Jul 20, 2020 |
| CORRESP · Letter to the SEC | Jul 10, 2020 |
| S-1 · Registration statement | Jul 2, 2020 |
All 14 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Jun 10, 2020 |
| DRS/A · Draft registration statement, amended | Jun 10, 2020 |
| UPLOAD · Letter from the SEC | Jun 4, 2020 |
| DRS · Draft registration statement | May 5, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 24, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 84.0M | 54.5M | 77.0M | 38.6M | 29.8M | 17.8M | 31.1M |
| Research and development | 316.9M | 221.6M | 189.1M | 184.5M | 116.4M | 66.5M | 45.0M |
| Operating income | -285.7M | -213.0M | -155.1M | -183.9M | -117.9M | -65.0M | -22.2M |
| Depreciation and amortization | 8.74M | 9.32M | 7.53M | 5.35M | 2.79M | 2.18M | 2.35M |
| EBITDA | -276.9M | -203.7M | -147.5M | -178.5M | -115.1M | -62.8M | -19.9M |
| Income before tax | -263.7M | -193.3M | -143.9M | -180.4M | -117.1M | -63.8M | -21.5M |
| Income tax | 760.0K | 270.0K | 0 | 0 | 131.0K | -20.5M | 239.0K |
| Net income | -264.5M | -193.6M | -143.9M | -180.4M | -117.2M | -43.2M | -21.7M |
| Earnings per share, basic | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 | -6.59 |
| Earnings per share, diluted | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 | -6.59 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 247.0M | 110.0M | 54.6M | 64.5M | 80.5M | 119.4M | 34.8M |
| Short-term investments | 244.7M | 215.2M | 161.8M | 2.90M | |||
| Receivables | 0 | 0 | 0 | 6.00M | |||
| Current assets | 606.8M | 619.4M | 295.5M | 318.4M | 311.1M | 298.4M | 39.4M |
| Property, plant and equipment | 22.5M | 17.8M | 16.8M | 17.2M | 11.3M | 6.67M | 3.87M |
| Total assets | 688.1M | 669.3M | 355.6M | 416.8M | 476.8M | 396.3M | 44.0M |
| Accounts payable | 11.2M | 11.5M | 6.40M | 5.06M | 6.65M | 3.41M | 1.60M |
| Current liabilities | 86.5M | 95.9M | 87.0M | 70.7M | 66.3M | 44.5M | 16.1M |
| Total liabilities | 149.4M | 142.3M | 155.1M | 113.1M | 134.5M | 106.1M | 53.6M |
| Shareholders' equity | 538.7M | 527.0M | 200.5M | 303.7M | 342.3M | 290.3M | -57.7M |
| Shares outstanding | 101.8M | 75.9M | 48.7M | 47.2M | 44.7M | 38.9M | 3.60M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -249.5M | -172.6M | -81.4M | -159.8M | -84.4M | -80.0K | 601.0K |
| Capital spending | -14.0M | -9.27M | -8.40M | -12.2M | -5.66M | -4.55M | -1.65M |
| Free cash flow | -263.5M | -181.9M | -89.8M | -172.1M | -90.0M | -4.63M | -1.05M |
| Cash from investing | 147.9M | -257.7M | 68.3M | 27.2M | -108.3M | -254.4M | 8.50M |
| Cash from financing | 238.6M | 485.7M | 3.22M | 117.2M | 153.9M | 339.0M | 126.0K |
| Change in cash | 137.0M | 55.4M | -9.85M | -15.4M | -38.7M | 84.5M | 9.22M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 3, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Oct 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 13, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 2, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 3, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 9, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 11, 2026 | Current report | SEC |
| 8-K · Current report | Jun 8, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 15, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Apr 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 8, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Mar 27, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 6, 2026 | Current report | SEC |
| 424B5 · Prospectus | Mar 6, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 28, 2026 | Offer document | SEC |
| 10-K · Annual report | Jan 28, 2026 | Annual report | SEC |
| 8-K · Current report | Jan 28, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 18, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 9, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 23, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Oct 22, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 22, 2025 | Current report | SEC |
| FWP · Free writing prospectus | Oct 22, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 22, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Oct 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 9, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| 8-K · Current report | Aug 22, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 9, 2025 | Results | SEC |
| 8-K · Current report | Jun 12, 2025 | Current report | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 8-K · Current report | May 19, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 23, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Apr 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 8, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Mar 28, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 28, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 28, 2025 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Mar 19, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 13, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 13, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 28, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 31, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 28, 2025 | Offer document | SEC |
| 10-K · Annual report | Jan 28, 2025 | Annual report | SEC |
| 8-K · Current report | Jan 28, 2025 | Results | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2024 | Insider trade | SEC |
This page holds 200 of 567 filings. Open Filings
Cap table
Built by 6ix from Nurix Therapeutics, Inc.’s releases · as of Sep 30, 2026
- Common shares
- 109,249,814
- Fully diluted
- 109,249,814
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 109,249,814 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 30, 2026 | 109,249,814 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Clay Siegall Other companies: Shattuck Labs, Inc. (President, Chairman of the Board of Immunome, Inc. · Since at least Mar 1, 2024); Tourmaline Bio Inc. (Director · Since at least Dec 13, 2023); Immunome, Inc. (President & Chief Executive Officer · Since at least Oct 2, 2023); Synlogic Inc (Director · Sep 30, 2015 – Jun 29, 2016 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 22, 2019 · Past); Ultragenyx Pharmaceutical Inc. (Director · Jan 30, 2014 – Aug 7, 2020 · Past); Seagen Inc (President & CEO, Director · Jan 31, 2006 – May 12, 2022 · Past) | Director · May 28, 2021 – May 5, 2022 · Past |
| Judith A. Reinsdorf Other companies: Toll Brothers, Inc. (Member of the Governance Committee · Since at least Dec 13, 2023); Enpro Inc. (Director · Since at least Sep 1, 2021); Cornerstone Building Brands Inc (Director · Aug 19, 2021 – Jul 25, 2022 · Past); Alexion Pharmaceuticals Inc (Director · Feb 5, 2018 – Jul 21, 2021 · Past); Dun & Bradstreet Holdings Inc. (Director · Jun 12, 2013 – Feb 8, 2019 · Past); Johnson Controls International plc (Executive VP & General Counsel · Mar 12, 2007 – Oct 12, 2017 · Past) | Director · Since at least Oct 1, 2021 |
| Lori Kunkel Other companies: Enliven Therapeutics, Inc. (Director · Since at least Apr 8, 2024); ORIC Pharmaceuticals, Inc. (Director · Since at least Jun 9, 2020); Tocagen Inc (Director · Jun 21, 2018 – Oct 4, 2019 · Past); Curis, Inc. (Director · Jan 22, 2018 – Jan 31, 2022 · Past); Loxo Oncology Inc (Director · Nov 2, 2017 – Feb 15, 2019 · Past) | Director · Jul 23, 2020 – May 19, 2025 · Past |
| Roy Baynes Other companies: Eikon Therapeutics, Inc. (Chief Medical Officer · Since at least Feb 4, 2026); Aardvark Therapeutics, Inc. (Director · Since at least Feb 12, 2025); Natera, Inc. (Director · Since at least Jul 25, 2018); Travere Therapeutics, Inc. (Director · Since at least Jul 19, 2016); Atara Biotherapeutics, Inc. (Director · Sep 11, 2018 – Jun 23, 2022 · Past) | Director · Since at least Mar 11, 2025 |
| Roger Dansey Other companies: Bicycle Therapeutics PLC (Director · Since at least Sep 8, 2025); Kronos Bio Inc (Director · Since at least Apr 20, 2023); Inovio Pharmaceuticals, Inc. (Director · Since at least May 13, 2021); Seagen Inc (President, R&D & CMO · May 21, 2018 – Dec 14, 2023 · Past) | Director · Since at least Nov 6, 2025 |
| Anil Kapur Other companies: Verastem, Inc. (Member, Audit Committee; Member, Compensation Committee; Member, Commercialization Committee · Since at least Oct 20, 2022); Geron Corporation (EVP, Corp Strategy & CCO · Dec 2, 2019 – Jun 10, 2024 · Past); Actinium Pharmaceuticals, Inc. (Delaware) (Chief Commercial Officer · Feb 6, 2018 – Jul 12, 2019 · Past) | Director · Since at least Oct 15, 2024 |
| David Lacey Other companies: Arcus Biosciences, Inc. (Director · Since at least May 21, 2020); Atreca Inc (Director · Jun 19, 2019 – Jun 13, 2023 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 18, 2020 · Past) | Director · Since at least Jul 23, 2020 |
| David V Goeddel Other companies: Tenaya Therapeutics, Inc. (Director · Since at least Jul 29, 2021); RAPT Therapeutics Inc (Director · Oct 30, 2019 – Nov 4, 2019 · Past); NGM Biopharmaceuticals Inc (Director · Apr 3, 2019 – Apr 5, 2024 · Past) | Director · Jul 28, 2020 – Jul 28, 2020 · Past |
| Jeffrey Tong Other companies: Septerna, Inc. (Chairman of the Board · Since at least Oct 24, 2024); Maze Therapeutics, Inc. (Director · Jan 30, 2025 – Jan 30, 2025 · Past); Rapport Therapeutics, Inc. (Director · Jun 6, 2024 – Jun 6, 2024 · Past) | Director · Jul 23, 2020 – May 6, 2021 · Past |
| Julia P. Gregory Other companies: Biohaven Ltd. (Director · Since at least Sep 28, 2022); Biohaven Pharmaceutical Holding Co Ltd (Director · Aug 2, 2017 – Oct 3, 2022 · Past); Lexicon Pharmaceuticals, Inc. (EVP and CFO · Feb 7, 2008 – Feb 7, 2008 · Past) | Chair · Since at least Jul 23, 2020 |
All 26 people
| Person | Seat |
|---|---|
| Leon Chen Other companies: Eikon Therapeutics, Inc. (Director · Since at least Feb 4, 2026); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Nov 16, 2022 · Past) | Director · Jul 23, 2020 – May 6, 2021 · Past |
| Stefani Wolff Other companies: Rain Oncology Inc (Director · Apr 22, 2021 – Jan 26, 2024 · Past); Principia Biopharma Inc (Chief Development Officer · Sep 13, 2018 – Sep 28, 2020 · Past) | EVP and COO · Aug 16, 2021 – Apr 30, 2023 · Past |
| Arthur T. Sands Other companies: Lexicon Pharmaceuticals, Inc. (President & CEO, Director · Feb 23, 2011 – Feb 28, 2014 · Past) | President, Chief Executive Officer, and Board Director · Since at least Jul 23, 2020 |
| Paul M Silva Other companies: Rapport Therapeutics, Inc. (Director · Since at least Jun 17, 2025) | Director · Since at least May 19, 2025 |
| Arati V. Rao | Chief Medical Officer · Since at least Nov 11, 2026 |
| Christine Ring | Chief Legal Officer · Since at least Apr 30, 2025 |
| Edward C Saltzman | Director · Since at least May 20, 2024 |
| Gwenn M. Hansen | Chief Scientific Officer · Since at least Jul 23, 2020 |
| Hans van Houte | Chief Financial Officer · Since at least Jul 23, 2020 |
| Jason Kantor | Chief Business Officer · May 15, 2025 – Nov 12, 2026 · Past |
| John Northcott | Chief Commercial Officer · Jan 12, 2026 – Nov 12, 2026 · Past |
| Pasit Phiasivongsa | Chief Technical Officer · Jan 13, 2025 – Nov 12, 2026 · Past |
| Pierre Beaurang | Chief Business Officer · Jul 23, 2020 – Aug 10, 2021 · Past |
| Robert Tjian | Director · Jul 23, 2020 – Jul 28, 2020 · Past |
| Wes Burwell | Chief Human Resources Officer · Since Aug 20, 2026 · Appointed, no departure found |
| Wes Burwell | Chief Human Resources Officer · Aug 20, 2026 – Nov 12, 2026 · Past |
Log in to ask 6ix AI your own questions about Nurix Therapeutics, Inc.